Engineered immune cells take aim at Hard-to-Treat ovarian cancer
NCT ID NCT07480954
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells designed to target the two markers found on their cancer. The goal is to see if this approach is safe and can shrink tumors. The study enrolls about 36 adults with recurrent ovarian, peritoneal, or fallopian tube cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can engineered immune cells target a common ovarian cancer protein?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?